1-4 of 4
Muhammad Jalaluddin, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Integrative Analysis of the Genomic and Transcriptomic Landscape of Relapsed/Refractory Multiple Myeloma Patients Treated With Venetoclax in Combination With Bortezomib and Dexamethasone: Biomarker Analyses From the Phase 3 BELLINI Study

Michael E. O'Dwyer, MD, Andrew Spencer, MBBS, FRACP, FRCPA, DM, Shaji K. Kumar, MD, Rakesh Popat, Philippe Moreau, MD, Monique Dail, PhD, Muhammad Jalaluddin, PhD, Xiaoqing Yang, PhD, Xin Lu, Zheng Zha, Fengjiao Dunbar, PhD, Deeksha Vishwamitra, PhD, Christine Mantis, PhD, Amal Melhem-Bertrandt, MD, Jeremy A. Ross, Simon J Harrison, MBBS MRCP (UK) PhDFRCPath (UK) FRACP
Journal: Blood
Blood (2020) 136 (Supplement 1): 40–41.
https://doi.org/10.1182/blood-2020-134710
Published: 2020
Journal Articles

A Phase 3, Open-Label, Randomized Study Evaluating the Efficacy and Safety of Navitoclax Plus Ruxolitinib Versus Best Available Therapy in Patients with Relapsed/Refractory Myelofibrosis (TRANSFORM-2)

Kimberley Dilley, MD MPH, Jason Harb, PhD, Muhammad Jalaluddin, PhD, Jessica E. Hutti, PhD, Jalaja Potluri, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 8.
https://doi.org/10.1182/blood-2020-139247
Published: 2020
Journal Articles

Updated Analysis of Bellini, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Philippe Moreau, MD, Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, Michele Cavo, Javier De La Rubia, Rakesh Popat, Cristina Gasparetto, MD, Vania T.M. Hungria, MD PhD, Hans Salwender, Kenshi Suzuki, MD PhD, Inho Kim, MD PhD, Francesca Gay, MD, Gábor Mikala, MD PhD, Elizabeth A Punnoose, PhD, Wan-Jen Hong, MD, Anjla Sood, MD, Muhammad Jalaluddin, PhD, Jeremy A. Ross, PhD, James E. Ward, MD, Paulo C. Maciag, MD PhD, Shaji K. Kumar, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1888.
https://doi.org/10.1182/blood-2019-126015
Published: 2019
Journal Articles

T(11;14) and High BCL2 Expression Are Predictive Biomarkers of Response to Venetoclax in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Biomarker Analyses from the Phase 3 Bellini Study

Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, Michele Cavo, Javier De La Rubia, Rakesh Popat, Cristina Gasparetto, MD, Vania T.M. Hungria, MD PhD, Hans Salwender, Kenshi Suzuki, MD PhD, Inho Kim, MD PhD, Philippe Moreau, MD, Andrew Spencer, MBBS, FRACP, FRCPA, DM, Michael E O'Dwyer, MD, Mamta Garg, MD FRCP, FRCPath, Elizabeth A Punnoose, PhD, Muhammad Jalaluddin, PhD, Jia Jia, PhD MBA, Xiaoqing Yang, PhD, Yan Sun, PhD, James E. Ward, MD, Paulo C. Maciag, MD PhD, Jeremy A. Ross, PhD, Shaji K. Kumar, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 142.
https://doi.org/10.1182/blood-2019-126094
Published: 2019